Novavax’s COVID-19 jab is more than 90 percent effective,including against coronavirus variants, the vaccine maker said Monday after a large-scale US study.
The jab “demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall”, the company said in a statement, adding “the study enrolled 29,960 participants across 119 sites in the U.S and Mexico to evaluate efficacy , safety and immunogenicity.”
“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” said Stanley C. Erck, novavax’s president and chief executive.
The company said it was “stored and stable at 2-8 c, allowing the use of existing vaccine supply chain channels for its distribution.
The Maryland-headquartered company said it intended to apply for regulatory approval by the third quarter of 2021.
Discussion about this post